Pramlintide and Insulin Degludec Interaction

Understanding the Pramlintide and Insulin Degludec Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Pramlintide belongs to the Amylin Analog class and Insulin Degludec belongs to the Ultra-Long-Acting Insulin class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Both drugs work to lower blood sugar, so taking them at the same time can cause your blood sugar to drop too low. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Pramlintide has 13 total documented interactions on file in this dataset, and Insulin Degludec has 12. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should monitor your blood sugar levels closely and your doctor may need to lower your insulin dose. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Pramlintide or Insulin Degludec based on a web page, speak with your prescriber or pharmacist before making any change.